D-galactose supplementation for the treatment of mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE): a trial of precision medicine after epilepsy surgery

Angel Aledo-Serrano (as.aledo@gmail.com)
La Milagrosa Hospital: Hospital La Milagrosa
https://orcid.org/0000-0003-4889-3365

Adián Valls-Carbó
Fundacion Iniciativa para las Neurociencias

Christina D. Fenger
Danish Epilepsy Center

Gudrun Groeppel
Johannes Kepler Universität Linz: Johannes Kepler Universitat Linz

Till Hartlieb
Schön Klinik Vogtareuth: Schon Klinik Vogtareuth

Irene Pascual
Ruber International Hospital: Hospital Ruber Internacional

Erika Herraez
Hospital Ruber Internacional

Borja Cabal
Hospital Ruber Internacional

Irene García-Morales
Hospital Ruber Internacional

Rafael Toledano
Hospital Ruber Internacional

Marcelo Budke
Hospital Ruber Internacional

Álvaro Beltran-Corbelli
Hospital Ruber Internacional

Sara Baldassari
Institut du cerveau et de la moelle épinière: Institut du cerveau et de la moelle epiniere

Roland Coras
Erlangen University Hospital: Universitätsklinikum Erlangen

Katja Kobow
Erlangen University Hospital: Universitätsklinikum Erlangen

David M. Herrera
Hospital Ruber Internacional

Antonio del Barrio
Hospital Ruber Internacional

Hans Atli Dahl
Erlangen University Hospital: Universitätsklinikum Erlangen

Isabel del Pino
Instituto de Neurociencias de Alicante

Stéphanie Baulac
Institut du cerveau et de la moelle épinière: Institut du cerveau et de la moelle epiniere
Research Article

Keywords: SLC35A2, somatic mutation, genetic epilepsy, developmental and epileptic encephalopathy, neurogenetics

Posted Date: February 22nd, 2023

DOI: https://doi.org/10.21203/rs.3.rs-2610838/v1

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Introduction: MOGHE is defined as mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy. Approximately half of patients with histopathologically confirmed MOGHE carry a brain somatic variant in the SLC35A2 gene encoding a UDP-galactose transporter. Previous research showed D-galactose supplementation results in clinical improvement in patients with a congenital disorder of glycosylation due to germline variants in SLC35A2. We aimed to evaluate the effects of D-galactose supplementation in patients with histopathologically confirmed MOGHE, with uncontrolled seizures or cognitive impairment and epileptiform activity at the EEG after epilepsy surgery (NCT04833322). Methods: Patients were orally supplemented with D-galactose for six months in doses up to 1.5 g/kg/day, monitored for seizure frequency including 24-hour-video-EEG recording, cognition and behavioral scores, i.e., WISC, BRIEF-2, SNAP-IV, SCQ and quality of life measures, before and 6 months after treatment. Global response was defined by >50% improvement of seizure frequency and/or cognition and behavior (Clinical Global Impression of “much improved” or better). Results. Twelve patients (aged 5-28 years) were included from three different centers. Neurosurgical tissue samples were available in all patients and revealed a brain somatic variant in SLC35A2 in six patients (non-present in blood). After six months of D-galactose supplementation a 50% reduction or higher of seizure frequency was achieved in 3/6 patients, with an improvement at EEG in 2/5 patients. One patient became seizure-free. An improvement of cognitive/behavioral features encompassing impulsivity (mean SNAP-IV -3.19 [-0.84; -5.6]), social communication (mean SCQ -2.08 [-0.63; -4.90]) and executive function (BRIEF-2 inhibit -5.2 [-1.23; -9.2]) was observed. Global responder rate was 9/12 (6/6 in SLC35A2-positive). Two patients presented gastrointestinal discomfort, solved after dose spacing or dose reduction. Conclusion: Supplementation with D-galactose in patients with MOGHE is safe and well tolerated. Although the efficacy data warrant larger studies, it might build a rationale for precision medicine after epilepsy surgery.

Key Points

- After 6 months of D-Galactose supplementation 3/6 MOGHE patients with seizures achieved a 50% reduction in seizure frequency, and one became seizure-free
- Improvements in social communication, impulsivity and executive function were also noted after the study
- D-Galactose is a safe and well tolerated treatment which may reduce seizure frequency and improve cognitive outcomes in MOGHE patients.

Introduction

Malformation of cortical development (MCD) is the most frequent disease condition histopathologically observed in surgical specimens of children undergoing surgery for refractory focal epilepsy[1]–[4]. Recently, a new type of MCD, mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE), was described in children and adults with refractory epilepsy, characterized by an increase in oligodendroglial cells and in addition to heterotopic neurons located in the white matter, among other features[5].

Since somatic variants of the mechanistic target of rapamycin (mTOR) were associated with focal cortical dysplasia (FCD) type 2, somatic mosaicism has been elucidated as a common cause of MCD[6]–[8]. Deep sequencing of brain specimens from patients with MOGHE have revealed a pathogenic variant in the SCL35A2 gene in approximately 45% of the patients [8]–[12]. The SCL35A2 gene encodes for the UDP-galactose transporter which is essential in protein and sphingolipid glycosylation taking place in the major Golgi apparatus and in the endoplasmic reticulum. Germline variants in SLC35A2 cause an X-linked congenital disorder of glycosylation (SLC35A2-CDG), a syndrome characterized by multiorgan involvement, including a neurodevelopmental disorder with seizures[13], [14].

A better understanding of the molecular mechanisms in developmental and epileptic encephalopathies (DEEs) have fostered repurposing of existing drugs that target specific cellular pathways[15]. This paradigm of precision medicine has been recently applied to mTORopathy-related epilepsies. For example, in tuberous sclerosis complex (TSC), caused by dysregulation of the mTOR pathway, rapamycin and other mTOR inhibitors demonstrated a reduction greater than 50% of seizure frequency compared with 15% treated with placebo[16]. As a result, rapamycin has been approved as a repurposed drug for the treatment of focal refractory seizures in patients with TSC[17], suggesting also preliminary effectiveness in preclinical studies of other mTORopathies caused by brain mosaicsisms[18]–[26].
In the context of UDP-galactose transporter-related pathology, a small trial with oral supplementation of D-galactose demonstrated clinical and developmental improvements in patients with germline variants in SLC35A2 (SLC35A2-CDG). Half of the patients (2/4) achieved seizure-freedom upon D-galactose supplementation [27]. Improvement in glycosylation [28] and clinical features such as alertness and interactivity [29] has also been observed in SLC35A2-CDG patients treated with D-galactose.

Resective surgery constitutes the first-choice treatment for drug-resistant focal epilepsy due to FCD and other MCDs. The overall rate of favorable epilepsy outcome ranges between 64–70% at 12 months after surgery [3], [30], [31]. However, a significant proportion of MCD patients are not rendered seizure free after surgery. Factors that may influence the effectiveness of resective surgery include the presence of multilobar pathology and difficulty in identifying and delineate lesions in neuroimaging [32], as well as incomplete resection due to the involvement of eloquent areas. Additionally, developmental and cognitive problems are not always solved after surgical treatment, with cognitive function being reported as unchanged or worsened after surgery up to 91% of patients [3]. Moreover, although surgery may improve cognitive outcomes in some patients especially in those who presented shorter duration of epilepsy and achieved seizure-free status access to epilepsy, surgery is typically delayed in most series [33], [34]. D-galactose is an easily accessible and well-tolerated treatment that allows the entry of galactose to the Golgi apparatus and endoplasmatic reticulum, thus improving the glycosylation process in UDP-galactose transporter-deficient cells. We hypothesized that treatment with D-galactose in histopathologically confirmed MOGHE patients may achieve improvements in epilepsy and neurodevelopmental outcomes. In this study we present the data from the first trial employing D-galactose supplementation in MOGHE patients, and the obtained results may indicate that D-galactose supplementation could be used as an effective disease-modifying treatment specially tailored to MOGHE patients.

**Methods**

**Patient recruitment**

This is a prospective multicenter single-arm study involving three European epilepsy centers: Hospital Ruber Internacional, HRI (Madrid, Spain), Kepler Universitätssklinikum, KU (Linz, Austria) and Schön Klinik Vogareuth, SKV (Vogareuth, Germany). Patients must meet the three inclusion criteria: 1) Age between 2 and 30 years at the start of the study, 2) histopathological diagnosis of MOGHE diagnosis of the resected brain tissue and 3) refractory epilepsy or cognitive impairment with ongoing epileptiform activity at the beginning of the study. Exclusion criteria was the presence of allergy to D-galactose or to other supplement components, and/or the presence of a germline variant in SLC35A2.

**Intervention**

Oral D-galactose was administered at a dose of up to 1.5g/kg daily for 18 weeks. A progressive titration similar to the already published protocol for SLC35A2-CDG patients was followed to minimize gastrointestinal side effects: a) weeks 0–6: 0.5g/kg daily; b) weeks 7–12: 1g/kg daily: and c) in weeks 13–18: 1.5 g/kg daily, following the already published schedule for SLC35A2-CDG patients [27]. Concomitant ASMs were not allowed to change during the first 6 months after initiation of D-galactose treatment. D-galactose was started at a minimum of 6 months after the epilepsy surgery and MOGHE histopathological diagnosis.

**Study protocol**

For each patient, investigators were asked to provide pseudo-anonymized information of the following items: (a) general clinical and demographic characteristics: sex, age, early development, neurological examination, age at first seizure, presence of autism spectrum or attention-deficit/hyperactivity disorder (ADHD), (b) seizures characteristics: type of seizures at onset, type of seizures at any time, presence of status epilepticus at any time, and epilepsy syndrome, (c) description of baseline electroencephalographic information, (d) MRI pattern, according to the Hartlieb et al. classification of MOGHE [2], and (e) treatment information: ASM received at any time, current ASM, age at surgery, type of resection, behavioral, cognitive and epilepsy outcome of surgery according to the Engel classification [35].

At the start of the study and after the treatment, the following variables were recorded:

- Seizure outcome: Monthly frequency at baseline, and at 1, 3 and 6 month(s) after the start of the treatment. Monthly seizure frequency was estimated as the number of seizures in the previous month divided by 30. Subjective changes in seizure duration and intensity reported by the patient and Clinical Global Impression (CGI [36]) Scale for epilepsy were also noted at 6 months.
• EEG outcome (epileptiform activity): In the HRI cohort, a 24-hour video-electroencephalographic recording was obtained before and after 6 months of treatment. For each patient, quantification of the epileptic activity per epoch was done, as well as the presence of bilateral synchrony and propagation of the activity.

• Cognitive and behavioral assessment: For each patient, CGI of cognition and behavior at 6 months was registered. In the HRI cohort of patients, at baseline and after 6 months of treatment, a comprehensive neuropsychological battery was administered, which included: Weschsler Intelligence Scale for Children (WISC-IV[37], in patients from 6–17 years), Weschsler Adults Intelligence Score (WAIS-IV, in patients older than 16 years), the Swanson, Behavior Rating Inventory of Executive Function (BRIEF-2[38], administered to the family and teachers), Conners’ continuous Performance Test (CPT-II[39]), Nolan and Pelham teacher and parent rating scale (SNAP-IV[40], [41], administered by caregivers and teachers) and Lifetime and Current Social Communication Questionnaire (L-SCQ and C-SCQ[42], administered by the caregivers). All ratings are expressed as percentiles, relative to a normative population, with increasing scoring in WISC and WAIS demonstrating an improvement, and in BRIEF-2, CPT-II, SNAP-IV and SCQ lower scores pointing to amelioration. BRIEF-2 indexes include the Behavior Regulation Index (BRI), which refers to the ability to regulate and monitor behavior and impulses; the Emotion Regulation Index (ERI) which refers to the ability to regulate emotional responses; Cognitive Regulation Index (CRI) which references to the ability to regulate thinking and attention; and Global Executive Composite (GEC), which is an overall summary score. To determine if changes in BRIEF were clinically meaningful, we relied on the Reliable Change Index (RCI) for BRI, ERI, CRI and GEC, using a 95% value for RCI, with thresholds at 9 for BRI and ERI and 8 for CRI and GEC. In this case, the differences were calculated for the evaluations of the family before and after treatment [38].

• Quality of life: in the HRI cohort, questionnaires measuring quality of life (Encuesta para la Calidad de Vida de niños con Epilepsia: CAVE[43] and Pediatric Quality of Life inventory: PedsQL[44]) at baseline and 6 months were provided to the caregivers and patients.

Discontinuation and adverse events were registered at any time of the study, including the time when the adverse event was noted.

Outcomes

• Seizure responder rate: Proportion of patients with 50% or greater reduction in the seizure frequency at 6 months compared to baseline, in patients who had non-controlled seizures at the start of the trial.

• Global responder rate: Proportion of patients with significant reduction in seizure frequency (50% or higher compared to baseline) activity and/or CGI for behavior or cognition of 2 (“much improved”) or better.

• Changes in CGI for epilepsy, cognition, and behavior.

• Significant reduction in epileptiform activity: Defined as a reduction of more than 50% of epileptiform activity or decrease in the presence of bilateral synchrony or propagation when a 50% reduction was not achieved. The disappearance of polyspike or fast activity in the follow up 24 h video-EEG was also a measure of EEG improvement.

• Changes in neuropsychological and behavioral scales.

Histopathological diagnosis

Assessment of the histopathological specimens was performed by an expert neuropathologist (IB/RC). Digitally scanned slides were made accessible for microscopic evaluation providing hematoxylin and eosin staining of all tissue blocks, Cresyl Violet Luxol Fast Blue (CV-LFB) stainings and/or immunohistochemistry for NeuN, MAP2, Olig2 and KI-67 in selected cases. The diagnosis of MOGHE was given if clusters of oligodendroglial cells were recognized at a density of more than 2,000/mm² at the grey-white matter junction, and an excess of heterotopic neurons in the white matter > 20/mm².

Detection of somatic variants

DNA was extracted from FFPE tissue and was subjected to Targeted sequencing with a gene panel. The panel contains 21 genes associated with FCD/MCD and MOGHE. NGS libraries were prepared by use of Twist Bioscience custom panel (Twist Bioscience) and paired-end sequenced on an Illumina platform (NovaSeq 6000, Illumina, San Diego, California, USA) (read depth range 251 – 30, 150x mean read depth). Reads were demultiplexed and aligned to GRCh37/hg19 human reference genome with BWA-MEM and variants were called with the use of Freebayes. Variants were filtered and analyzed by use of Golden Helix VarSeq 2.2.3 (Golden Helix Inc., Bozeman, Montana, USA). The Varseq filter parameters were as follows: 1) aphred quality score (QUAL) > 10; 2) Variant allele
frequencing (VAF) > 0.02; 3) with the sample read depth (DP) set to ≥ 10, and 4) finally, variants should not have been observed more than once in homozygous or hemizygous state, hence the GnomAD Homo/Hemi filter was set to AC < 1.

All low frequency variants were evaluated according to the ACMG guidelines (Richards et al., 2015, Genet Med 17(5):405 – 24). Included in this evaluation were database searches like Human Gene Mutation Database (HGMD), the Genome Aggregation Database (gnomAD, release 2.1.1), ClinVar, and dbSNP(155). Predictions on protein level were obtained from dbNSFP Functional Predictions and Cores 3.0 database. All patients had a normal previous germline genetic testing (a gene panel or exome sequencing performed in blood or saliva sample).

Protocol Approvals and Patient Consents

Written informed consent for participation/publication in this study was obtained from all parents or legal guardians. Protocol and design of the study was reviewed by the ethics committee of HRI. The protocol was approved and published in clinicaltrials.gov: NCT04833322.

Statistical analysis

Statistical analysis and graphical representation were performed in R[45] and RStudio[46]. Qualitative measures were expressed in fraction and percentage, whereas quantitative measures are shown as median and range, except for SNAP-IV, where interquartile range is shown. Associations between two qualitative measures are studied with Chi Square test or Fisher test when appropriate. Analysis of the change of the quantitative tests over time was performed with generalized linear mixed models, adjusting by id and evaluator as random effects when necessary, and using time as a fixed effect. No interactions nor subgroup analyses were performed due to the low number of observations. Statistical associations are expressed in mean changes of the measure, 95% confidence interval and p value.

Results

Twelve patients (3 females, 5–16 years; 9 males, 9–28 years) were enrolled in the study. In 6/12 patients, a SLC35A2 brain-specific mosaic variant was detected (table 2). Two of the variants were nonsense, one of them an inframe deletion of one amino acid and two of them were missense variants, and the last variant was a non-coding variant in the 3’UTR. The two nonsense variants appeared relatively early in the transcript and are therefore likely to lead to nonsense mediated decay. The inframe deletion of one amino acid was previously seen in a patient with early-onset epilepsy and congenital disorder of glycosylation [8, 20, 22]. Likewise, the p. (Gly282=/>Arg) amino acid substitution was observed in a patient with congenital disorder of glycosylation [41]. The two remaining variants, the missense and the noncoding 3’ UTR variant are not previously observed. Clinical and radiological baseline features of the patients are shown in table 1. Median time from first seizure and from resective surgery to the start of the trial was 141 months (range 55–186) and 30 months (range 6-120), respectively. Of note, 6 patients had ongoing seizures and 6 were seizure-free before the start of the study but showed cognitive impairment and epileptiform activity at the baseline video-EEG monitoring.

Drug administration

All patients received D-galactose, at a median dose of 1.15 g/kg per day (range 1.3–0.5 g/kg day) and a median total daily dose of 50 g (range 40–66 g). Frequency of administration ranged from 1 administration per day to 4 times daily. Patients reached the maximum dose at median of 12 weeks (range 4–16 weeks) and were followed a median of 12 months (range 7–16 months).

Safety

None of the patients reported dietary changes related to the administration of the drug, but in 2/12 adverse events related to the administration appeared. In case #3, nausea was reported, which was resolved when medication intake was separated in different doses over the course of the day. In the other case (#12), skin rash, gastrointestinal discomfort and diarrhea appeared at the daily dose of 66 g (1.32 g/kg) and improved after symptomatic treatment and a reduction to daily 45 g (0.9 g/kg. In regard to patient #6 adherence to treatment could not be guaranteed due to refusal of the patient and she discontinued the treatment because of lack of efficacy at 12 months.

Seizure outcomes:
In 4/6 patients with seizures, a 50% seizure reduction was achieved at 1 month after the target dose, while no change was noted in 2/6. No increase in the seizure frequency was reported in the cohort. The 50% reduction was maintained at six months in all but one patient (3/6), who came back to her baseline seizure frequency after the initial response (seizure responder rate of 50%). Also, an improvement in seizure intensity and duration was noted in all the patients with reduced seizure frequency (3/3) at 6 months. One of the patients (patient #8) became seizure-free after the treatment.

Continuous 24h video-EEG was available before and after 6 months of treatment in 5/12 patients. In 2/5 there was a significant reduction in the epileptiform activity, while in 3/5 no change was noted in the EEG. Seizure reduction was associated with a decrease in epileptiform activity in 2/3 patients.

Cognitive, behavioral, and quality of life outcomes

CGI for cognition was reported as “much improvement” in 8/10 patients, while in 2 of them this change was “minimal” or “none”. Regarding behavior, no change was reported in 6/11 patients, and just 5/11 noted a “minimal improvement” (considered as non-significant).

Although no statistically significant differences were found in total WISC scores (before treatment 68 range [59;87], after treatment 66 range [61;86], p = 0.254), patients exhibited a non-significant trend towards higher scores in verbal comprehension indexes of WISC after treatment (mean increase 6.5 [0.5;12.42] p = 0.056; n = 6 for comparison). In general, BRIEF-2 indexes tended to improve in the whole cohort (Fig. 1), while before the treatment 27/157 (17.2%) tests were abnormal, after 6 months of treatment just 10/120 (8.3%, p = 0.05) were under the normal range. When analyzing each subtest separately, inhibit score showed a significant reduction after treatment (mean reduction 5.2 CI [1.23; 9.2], p = 0.02), and almost significant in the behavior regulation index (mean reduction 6.4 CI [0; 12.8], p = 0.051). Before treatment, 3/8, 4/8, 3/6, and 2/6 patients had clinically elevated scores (percentile > 65) on the BRI, ERI, CRI and GEC. After treatment, 4/7, 2/6, 0/4 and 1/4 patients achieved a clinically meaningful improvement (RCI values > 95%) in BRI, ERI, CRI and GEC. No association was found between meaningful improvements in BRIEF indexes (BRI p = 0.5, ERI p = 0.4, CRI p = 1, GEC p = 1) and clinically elevated scores before treatment or > 50% reduction achievement in seizure frequency (BRI p = 1, ERI p = 1, CRI p = 1, GEC p = 1).

Also, the treatment reduced the SNAP-IV values of the patients (mean reduction 3.19 CI [0.84; 5.6], p = 0.01), Fig. 2) and the current SCQ (mean reduction 2.08 CI [0.63;4.90], p = 0.03). Only patient #6 showed an increase in the SNAP-IV and BRIEF-2 values (Fig. 2). No statistically significant differences were found in CPT-II and quality of life scores CAVE, PedsQL (supplementary table 1).

Global responder rate

Nine (9/12) patients showed a global response (either in seizure or cognitive/behavioral outcomes, Fig. 3). Notably, in 6/9 responder cases, a pathogenic variant in SLC35A2 was found, thus global responder rate was 6/6 in SLC35A2-positive cases, while it was 3/6 in the SLC35A2-negative group.

Case study

Patient #8 was a 29-year-old male, with normal neurodevelopment and university education, who had onset of a drug-resistant focal epilepsy at the age of 15 years, despite treatment with more than 10 ASMs, including a clinical trial with padsevonil. Seizures were frequent (8–10 per month) and classified as focal impaired awareness, with postictal dysphasia. Video-EEG and magnetoencephalography demonstrated epileptiform activity in the left central and parietal regions, and MRI showed a mild abnormality of the gyral architecture in the left parietal operculum and posterior temporal region. A stereo-EEG was performed over that region, including radiofrequency thermocoagulation obtaining temporary improvement in seizure frequency and intensity. Due to the proximity to eloquent areas, a new intracranial EEG with subdural grid was performed, with language mapping. After that, a partial parietal resection, without resecting some of the areas related to seizure-onset zone due to language involvement, was made at the age of 28 years. This confirmed the histopathological diagnosis of MOGHE in the resected tissue. Gene panel testing on saliva was negative, however targeted sequencing of the resected brain tissue revealed a pathogenic variant [c.322C > T; p.(Gln108*)] in SLC35A2, with a variant allele frequency of 17%. The clinical picture of the patient was compatible with the drug resistant focal epilepsy MOGHE phenotype, according to Barba et al[3]. Six months after the surgery, the patient still had 4 seizures/month despite treatment with lamotrigine, lacosamide, clobazam and oxcarbazepine. The patient was enrolled in this trial and was being assigned to a target daily dose of 50g D-galactose (0.5 g/kg/day). In the first month after the treatment, the patient became seizure-free, with a video-EEG
showing a 90% reduction in the epileptiform activity (Fig. 3). The seizure-freedom was maintained until last-follow up (12 months after treatment initiation).

**Discussion**

In the present study we demonstrated the feasibility, safety, and tolerability of D-galactose supplementation in a cohort of 12 patients with MOGHE, as well as preliminary evidence of the efficacy of the treatment. In our cohort we found a maintained 50% or higher seizure reduction in half of the patients, and an improvement in some cognitive and behavioral outcomes, such as impulsivity (mean reduction of SNAP-IV 3.19 [0.84; 5.6]) and social communication (mean reduction of current SCQ 2.08 CI [0.63;4.90]). Furthermore, a global improvement in executive function was observed, even though it was only possible to find statistical significance in the inhibit subitems of BRIEF-2. Global responder rate, defined as proportion of patients with significant response in either seizure or cognitive/behavioral outcomes, was 9 out of 12.

Overall, the treatment was safe and well tolerated but 2/12 patients experienced mild gastrointestinal discomfort, which was solved after dose adjustment and spacing. One patient discontinued the treatment before the six months follow-up because of lack of efficacy and difficulties in adherence. Despite our cohort is small, interestingly, the responder proportion was higher in SLC35A2-positive patients (6/6) compared to those without an SLC35A2 variant (3/6). Of note, half of the patients were seizure-controlled at the beginning of the trial, showing that D-galactose might be effective for cognitive/behavioral outcomes even in patients who remains seizure-free after epilepsy surgery.

Although the samples in both studies are small, our findings are in line with the results of D-galactose supplementation in SLC35A2-CDG, where there was seizure improvement (2/4), and significant improvement in the cognitive profile[27]. Even though our patients already underwent epilepsy surgery, our study found that D-galactose treatment can improve epilepsy and cognitive outcomes. Some explanations for that are the presence of MRI undetected multilobar involvement[32] or surgical remnants, which is common in patients with MOGHE[3]. We hypothesize that D-galactose supplementation can improve the glycosylation in the remaining cells after surgery, ameliorating the functionality of them.

Regarding non-responder patients, it is remarkable that all of them were SLC35A2-negative. However, SLC35A2 subgroup analysis should be taken with caution. Although in our series, the frequency of SLC35A2 positivity in MOGHE patients (6/12) is similar to other series reporting around a 45% of somatic pathogenic SLC35A2 variants in MOGHE brain samples[9], the lesser efficacy in SLC35A2 negative patients cannot be completely attributed to this finding. Variants in other genes of the N-glycosylation pathway or the lack of sensitivity of the sequencing techniques can also explain the SLC35A2 negativity. Thus, we cannot ascertain whether D-galactose is more effective in SLC35A2 positive patients. Furthermore, specific types of SLC35A2 variants may have different responses to D-galactose, which was not explored due to the low sample size of our study.

In addition, the response might be worse in patients with severe phenotypes of developmental and epileptic encephalopathies and longer epilepsy duration. In our cohort, the best responder (case study, patient #8), who became completely seizure-free after D-galactose supplementation, had a “late-onset” form of MOGHE. He had onset of intractable focal epilepsy at the age of 15 years but no learning difficulties or cognitive impairment. Larger samples are warranted to further elucidate this finding.

One of the main limitations of our study is its unblinded, non-placebo-controlled character and improvement being scored by the treating physicians. Future studies should include a double-blind randomized placebo-controlled design to increase the evidence and obtain more granular data. Since this is a relatively difficult-to-diagnose and rare condition, a double-blind, cross-over control study design could be the most affordable approach. Another limitation is the low number of patients, the lack of complete neuropsychological evaluation in centers other than HRI and the short follow-up period, which might have underpowered the statistical analysis. Although the 6 months follow up could be considered as a limitation, the assessment tools (37–42) are parent-reported scales and do not show learning bias.

To date, this is the first pilot study of D-galactose in a cohort of histologically diagnosed MOGHE patients after surgery. Although these results warrant larger and controlled studies, they also suggest a window of opportunity to improve cognitive and seizure outcomes after surgery and provide preliminary evidence of the efficacy of precision medicine in this subgroup of patients.

**Declarations**
Data Availability Statement

De-identied data will be shared on request from any qualified investigator.

Funding Statement

IB's work was partially funded by the German Research Council (DFG Bl 421/4-1, DFG Bl 421/5-1).

Acknowledgments

IB’s work was partially funded by the German Research Council (DFG Bl 421/4-1, DFG Bl 421/5-1).

Patients consent

Written informed consent for participation/publication in this study was obtained from all parents or legal guardians

Author contribution

AAS and AGN conceived the original idea of the study. AAS, AGN, GG, IGM, RT, EH, BC, ABC, DMH, AB, TH and MB recruited and evaluated the patients. RC, KK and IB performed the histopathological diagnosis. SB, SB, RM, CDF and IP carried out the genetics. IP performed the neuropsychological evaluation. AAS and AVC wrote the original manuscript. AVC performed the statistical analysis and created the plots. AAS, AVC, SB, IB, RM and AGN revised the manuscript.

Conflict of interest

None of the authors has conflicts of interest to disclose.

Ethical Publication Statement

We confirm that all the authors have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

References


Tables
Table 1
Bold letters seizures indicate the type of seizures present at the time of the start of the study. 1 = Epilepsy outcome according to Engel classification, MRI = Magnetic Resonance Imaging, MSF = monthly seizure frequency at the start of the study, AT = asymmetric tonic seizures, AS = asymmetric spasms, TA = tonic-atonic, FIAMF = focal impaired awareness with motor facial, FIA = focal impaired awareness, G = gelastic, Ak = akinetic, Aph = Aphasic, LG = Lennox Gastaut syndrome, SE = Status epilepticus, ID = intellectual disability, Reg = regressive episode during development, Agg = aggressivity, FCD = focal cortical dysplasia, SL = sublobectomy, ST = subtotal lobectomy, WR = wider resection, LMR = limited medial resection L = Left, R = Right, att = Attention, lang = Language, beh = Behavior, m = months, y = years

<table>
<thead>
<tr>
<th>ID</th>
<th>Age, sex</th>
<th>Type of seizures, (epileptic syndrome), age at first seizure</th>
<th>MSF</th>
<th>SE?</th>
<th>Cognitive syndrome, age at developmental concern</th>
<th>MRI pattern, age of discovery</th>
<th>Localization</th>
<th>Surgery, age at surgery</th>
<th>Seizure outcome after surgery</th>
<th>Cognitive outcome after surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>13, M</td>
<td>AS, TA, FIAMF, 14 m</td>
<td>0</td>
<td>Y</td>
<td>Reg, mild ID, ADHD, 22 m</td>
<td>Pattern II, 4 y</td>
<td>L frontal</td>
<td>SL, 5 y, WR 9y</td>
<td>I A</td>
<td>Better att, lang, beh</td>
</tr>
<tr>
<td>#2</td>
<td>13, M</td>
<td>AT, TA, FIA, Ak, 24 m</td>
<td>0</td>
<td>Y</td>
<td>Reg, mild ID, Au, ADHD, 24 m</td>
<td>Pattern I, 4 y</td>
<td>R frontal</td>
<td>SL, 5 y, WR 5y</td>
<td>I A</td>
<td>Better att, beh</td>
</tr>
<tr>
<td>#3</td>
<td>9, F</td>
<td>AS, TA, FIA, G, Ak, 18 m</td>
<td>90</td>
<td>Y</td>
<td>Reg, moderate ID, Au, ADHD, 24 m</td>
<td>Pattern I, 3 y</td>
<td>R frontal</td>
<td>SL, 3 y, WR 5y</td>
<td>IV A</td>
<td>Better att, lang, beh</td>
</tr>
<tr>
<td>#4</td>
<td>16, F</td>
<td>AS, TA, G, Ak, (West), 6 m</td>
<td>0</td>
<td>Y</td>
<td>Reg, moderate ID, Au, ADHD, Agg, 20 m</td>
<td>Pattern I, 9 y</td>
<td>R frontal</td>
<td>SL, 10 y</td>
<td>I A</td>
<td>Better att, lang, worse beh</td>
</tr>
<tr>
<td>#5</td>
<td>16, F</td>
<td>AT, TA, Ak, 34 m</td>
<td>0</td>
<td>Y</td>
<td>Mild ID, ADHD, 40 m</td>
<td>Pattern II, 5 y</td>
<td>R frontal</td>
<td>SL, 7 y</td>
<td>I A</td>
<td>Better att, beh</td>
</tr>
<tr>
<td>#6</td>
<td>6, F</td>
<td>AS, (West), 5 m</td>
<td>0</td>
<td>Y</td>
<td>Mild ID, ADHD, 8 m</td>
<td>Pattern I, 1 y</td>
<td>R frontal</td>
<td>ST 3y</td>
<td>I A</td>
<td>Better att, beh</td>
</tr>
<tr>
<td>#7</td>
<td>17, M</td>
<td>AT, TA, Ak, G, FIAMF, (LG), 18 m</td>
<td>105</td>
<td>N</td>
<td>Reg, severe ID, Au, ADHD, Agg, 18 m</td>
<td>Pattern I, 3 y</td>
<td>L frontal</td>
<td>ST, 7 y</td>
<td>IV B</td>
<td>No change</td>
</tr>
<tr>
<td>#8</td>
<td>29, M</td>
<td>AT, Aph, FIAMF, 180 m</td>
<td>105</td>
<td>Y</td>
<td>Normal, Subtle dysgiria, 16 y</td>
<td>L parietal</td>
<td>LMR 28 y</td>
<td>IV A</td>
<td>Better att, worse lang</td>
<td></td>
</tr>
<tr>
<td>#9</td>
<td>14, M</td>
<td>AS, (West), 6 m</td>
<td>60</td>
<td>N</td>
<td>Mild ID, Au, ADHD, Agg, 6 m</td>
<td>Normal, 12 y</td>
<td>L frontal</td>
<td>SL, 13 y</td>
<td>IV A</td>
<td>No change</td>
</tr>
<tr>
<td>#10</td>
<td>12, M</td>
<td>AS, (West), 4 m</td>
<td>90</td>
<td>N</td>
<td>Mild ID, Au, 4 m</td>
<td>FCD, 11 y</td>
<td>L frontal</td>
<td>SL, 11 y</td>
<td>IV A</td>
<td>General improvement</td>
</tr>
<tr>
<td>#11</td>
<td>9, M</td>
<td>AT, G, 24 m</td>
<td>0</td>
<td>Y</td>
<td>Mild ID, ADHD, 48 m</td>
<td>N/A</td>
<td>R frontal</td>
<td>ST, 7 y</td>
<td>I A</td>
<td>General Improvement</td>
</tr>
<tr>
<td>#12</td>
<td>9, M</td>
<td>AT, 18 m</td>
<td>1</td>
<td>N</td>
<td>Reg, severe ID, Au, Agg, 12 m</td>
<td>FCD, 3 y</td>
<td>L fronto-temporal</td>
<td>ST frontal and anterior temporal, 6 y</td>
<td>IV A</td>
<td>Slow cognitive progress</td>
</tr>
</tbody>
</table>

Page 12/17
Table 2
Summary of genetic findings. In all cases the transcript was NP_001035963.

<table>
<thead>
<tr>
<th>ID</th>
<th>SLC35A2 cDNA change</th>
<th>Aminoacid change</th>
<th>Type of variant</th>
<th>Annotation</th>
<th>Level of mosaicism</th>
<th>Previously described variants</th>
</tr>
</thead>
<tbody>
<tr>
<td>#2</td>
<td>c.844G &gt; A</td>
<td>p.(Gly282Arg)</td>
<td>Missense</td>
<td>Pathogenic</td>
<td>32.6%</td>
<td>Yes[47]</td>
</tr>
<tr>
<td>#4</td>
<td>c.*1474C &gt; T</td>
<td>3'-UTR variant</td>
<td>3' UTR</td>
<td>Likely pathogenic</td>
<td>30%</td>
<td>No</td>
</tr>
<tr>
<td>#5</td>
<td>c.466_468delTCC</td>
<td>p.(Ser156del)</td>
<td>Inframe deletion</td>
<td>Pathogenic</td>
<td>35.1%</td>
<td>Yes[13], [27], [29]</td>
</tr>
<tr>
<td>#8</td>
<td>c.322C &gt; T</td>
<td>p.(Gln108*)</td>
<td>Stop gain</td>
<td>Pathogenic</td>
<td>17%</td>
<td>No</td>
</tr>
<tr>
<td>#11</td>
<td>c.533G &gt; A</td>
<td>p.(Gly178Asp)</td>
<td>Missense</td>
<td>Likely pathogenic</td>
<td>19.1%</td>
<td>No</td>
</tr>
<tr>
<td>#12</td>
<td>c.580_616dup</td>
<td>p.(Val206Alafs*28)</td>
<td>Stop gain</td>
<td>Pathogenic</td>
<td>9%</td>
<td>No</td>
</tr>
</tbody>
</table>

Supplementary Table
<table>
<thead>
<tr>
<th></th>
<th>Before</th>
<th>After</th>
<th>p.value</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WISC (median, range)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total WISC</td>
<td>68 [53;87]</td>
<td>66 [61;86]</td>
<td>0.254</td>
<td>5</td>
</tr>
<tr>
<td>Verbal comprehension index</td>
<td>78 [68;84]</td>
<td>82 [78;89]</td>
<td>0.056</td>
<td>5</td>
</tr>
<tr>
<td>Perceptual reasoning index</td>
<td>66 [51;107]</td>
<td>69 [49;92]</td>
<td>0.665</td>
<td>5</td>
</tr>
<tr>
<td>Working memory index</td>
<td>74 [50;82]</td>
<td>72 [55;100]</td>
<td>0.709</td>
<td>4</td>
</tr>
<tr>
<td>Processing speed index</td>
<td>74 [60;88]</td>
<td>81 [64;92]</td>
<td>0.44</td>
<td>4</td>
</tr>
<tr>
<td><strong>BRIEF-2 (median, range)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inhibition</td>
<td>58 [47;85]</td>
<td>53 [47;78]</td>
<td>0.02</td>
<td>6</td>
</tr>
<tr>
<td>Self-monitor</td>
<td>64 [43;82]</td>
<td>56.5 [43;76]</td>
<td>0.445</td>
<td>6</td>
</tr>
<tr>
<td>Shift</td>
<td>66 [50;85]</td>
<td>56 [46;85]</td>
<td>0.280</td>
<td>6</td>
</tr>
<tr>
<td>Emotional control</td>
<td>57 [43;96]</td>
<td>51 [39;80]</td>
<td>0.636</td>
<td>6</td>
</tr>
<tr>
<td>Initiate</td>
<td>60 [38;84]</td>
<td>58 [41;75]</td>
<td>0.720</td>
<td>5</td>
</tr>
<tr>
<td>Working memory</td>
<td>70 [46;83]</td>
<td>66 [56;80]</td>
<td>0.148</td>
<td>6</td>
</tr>
<tr>
<td>Plan/organize</td>
<td>66 [38;81]</td>
<td>59 [50;90]</td>
<td>0.807</td>
<td>6</td>
</tr>
<tr>
<td>Task Monitor</td>
<td>63 [41;83]</td>
<td>56 [39;71]</td>
<td>0.08</td>
<td>6</td>
</tr>
<tr>
<td>Organization of materials</td>
<td>56 [42;97]</td>
<td>62 [40;94]</td>
<td>0.781</td>
<td>6</td>
</tr>
<tr>
<td>Behavior Regulation index</td>
<td>60 [48;85]</td>
<td>55 [48;69]</td>
<td>0.051</td>
<td>6</td>
</tr>
<tr>
<td>Emotion regulation Index</td>
<td>58 [48;87]</td>
<td>50 [40;81]</td>
<td>0.458</td>
<td>5</td>
</tr>
<tr>
<td>Cognitive Regulation index</td>
<td>65 [40;91]</td>
<td>61 [41;84]</td>
<td>0.678</td>
<td>5</td>
</tr>
<tr>
<td>Global Executive Index</td>
<td>66 [43;88]</td>
<td>60 [49;84]</td>
<td>0.229</td>
<td>5</td>
</tr>
<tr>
<td><strong>CPT-II (median, range)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>55.2 [43.6;97.7]</td>
<td>50 [29.1;58.8]</td>
<td>0.241</td>
<td>2</td>
</tr>
<tr>
<td>Vigilance</td>
<td>89.3 [49.8;91.9]</td>
<td>79 [14.6;90.9]</td>
<td>0.308</td>
<td>5</td>
</tr>
<tr>
<td>Sustained attention</td>
<td>67.9 [25.1;99]</td>
<td>53.6 [22.5;96]</td>
<td>0.842</td>
<td>5</td>
</tr>
<tr>
<td>Impulsivity</td>
<td>52.3 [11;93.8]</td>
<td>62.4 [20.1;71]</td>
<td>0.645</td>
<td>5</td>
</tr>
<tr>
<td>Reaction time</td>
<td>87.1 [37.9;99]</td>
<td>79 [16.4;97.5]</td>
<td>0.288</td>
<td>5</td>
</tr>
<tr>
<td>Rigidity</td>
<td>74.5 [42;96.8]</td>
<td>53.2 [32.8;80.8]</td>
<td>0.256</td>
<td>5</td>
</tr>
<tr>
<td>SNAP-IV (median, IQR)</td>
<td>15 [9;17]</td>
<td>8.5 [4.2;14]</td>
<td>0.01</td>
<td>24 (7)</td>
</tr>
<tr>
<td><strong>SCQ (median, range)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>7 [2;19]</td>
<td>7 [0;11]</td>
<td>0.032</td>
<td>5</td>
</tr>
<tr>
<td>Lifetime</td>
<td>8 [3;27]</td>
<td>9 [4;25]</td>
<td>0.721</td>
<td>5</td>
</tr>
<tr>
<td>Quality of life (median, range)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAVE scale</td>
<td>35 [19;37]</td>
<td>34 [23;38]</td>
<td>0.34</td>
<td>4</td>
</tr>
<tr>
<td>Peds-QL</td>
<td>43 [28;62]</td>
<td>47 [15;54]</td>
<td>0.861</td>
<td>5</td>
</tr>
</tbody>
</table>

Supplementary table 1: Analysis of neuropsychological evaluation.
Figures

**Figure 1**

Boxplot of SNAP-IV values before and after treatment. SNAP-IV was evaluated one or more times at every time point (baseline and at 6 months) by the school, mother and father. Each dot represents an evaluation for each patient. If one of the evaluation was missing, the dot is not represented. Although some patients increased their values, in general, a global reduction in the score was noted (column All).

**Figure 2**

Changes in the BRIEF-2 score after the treatment. BRIEF-2 contains multiple subtests (Inh, SM, Sh, EC, Ini, WM, P, TM and OM) as well as some indexes (BRI, ERI, CRI, GEI). See methods for more information about BRIEF-2 test. Red dots represent the scaled scoring of each subtest at baseline, while blue dots are the scaled measures after 18 weeks of treatment. Blue arrows represent improvement in
the scoring, while red arrows worsening. Light grey area is the area with a scoring above percentile 70, dark grey area is the percentile between 65 and 70, light green percentile 60 and 65, and dark green percentile below 60. Dotted line represents percentile 50. Note how in most of patients there is an improvement in the values of the test, achieving in most of the cases normal. Inh = Inhibit, SM = Self-Monitor, Sh = Shift, EC = Emotional control, Ini = Initiate, WM=Working memory, P=Plan/organize, TM = Task-Monitor, OM=Organization of Materials, BRI = Behavior Regulation Index, composed by Sh and EC, ERI = Emotion Regulation Index, composed by Ini, WM, P, TM and OM, CRI = Cognitive Regulation Index, composed by Inh and SM, GEI = Global Executive Index, a composite of all indexes.

**Figure 3**

Flowchart diagram of the outcomes. Just main outcome measures are shown in the chart, for details about neuropsychological and EEG outcomes can be found in the main text. Epi = refractory epileptic cohort, cog = cognitively impaired with epileptic activity (seizure-free) cohort, SL
Figure 4

Changes in the EEG epileptiform activity in patient #8: A) Before D-galactose, with almost continuous focal activity over the right central-parietal area; B) After 6 months of supplementation with D-galactose, with EEG almost normalized.